Adverum is a gene therapy company that innovate and produce medicines for rare and eye diseases that do not have many existing treatments. Adverum focuses on 7 key areas such as: wAMD, A1T Deficiency, HAE, FA, Severe allergy, Color vision deficiency, and XLRS. Adverum biotechnologies was founded in 2006, and it is headquartered in Menlo park, California. The company was previously known as Avalanche Technologies but changed its name to Adverum Biotechnologies in May 2016. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.